Atopic Dermatitis Market Report 2026

The atopic dermatitis market size has grown rapidly in recent years. It will grow from $9.88 billion in 2025 to $11.34 billion in 2026 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to increasing prevalence of chronic skin conditions, wider availability of topical corticosteroids, expansion of dermatology care services, growing awareness of eczema management, improved diagnostic accuracy.

The atopic dermatitis market size is expected to see rapid growth in the next few years. It will grow to $19.53 billion in 2030 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to increasing adoption of biologics and JAK inhibitors, rising focus on personalized dermatology treatments, expansion of injectable therapy options, growing investment in dermatology research, increasing demand for long-term symptom control. Major trends in the forecast period include increasing adoption of biologic therapies, rising demand for targeted immunomodulators, growing focus on long-term disease management, expansion of advanced topical formulations, enhanced emphasis on patient-centric treatment.

The growing demand for personalized medicine is anticipated to drive the expansion of the atopic dermatitis market in the coming years. Personalized medicine is an innovative approach to healthcare and medical treatment that customizes medical decisions, practices, interventions, and drug therapies to the individual patient. In atopic dermatitis, personalized medicine involves identifying specific genetic and molecular factors that influence the disease, allowing the development of targeted therapies tailored to each patient’s unique characteristics. This method not only improves treatment effectiveness but also reduces the risk of adverse effects. For example, in February 2024, the Personalized Medicine Coalition, a US-based advocacy organization for tailored medical treatments, reported that the FDA approved 16 new personalized therapies for rare disease patients in 2023, compared to six in 2022. As a result, the rising demand for personalized medicine is fueling the growth of the atopic dermatitis market.

Major companies in the atopic dermatitis market are focusing on developing innovative therapies such as IL-31 receptor antagonists to manage chronic itch, enhance control of skin symptoms, and minimize systemic side effects compared to conventional corticosteroids or immunosuppressants. An IL-31 receptor antagonist functions by blocking the IL-31 signaling pathway, which plays a direct role in itch sensation and inflammation, providing a more targeted approach than general immune suppression. For example, in December 2024, Galderma, a Switzerland-based dermatology company, received FDA approval for Nemluvio (nemolizumab), the first monoclonal antibody that specifically targets the IL-31 receptor alpha to inhibit IL-31 signaling in moderate-to-severe atopic dermatitis. The therapy is delivered via subcutaneous injection, binds to the IL-31 receptor to prevent activation by the IL-31 cytokine, and has demonstrated in clinical trials rapid relief from itch and significant improvement in skin symptoms when used alongside topical treatments.

In September 2024, Organon, a US-based healthcare company, acquired Dermavant Sciences Ltd. for up to US$ 1.2 billion. Through this acquisition, Organon intends to broaden its dermatology and immune-mediated skin disease portfolio by incorporating Dermavant’s VTAMA® (tapinarof) cream and furthering its development for atopic dermatitis in both adults and children. Dermavant Sciences Ltd. is a US-based immuno-dermatology company that offers VTAMA® (tapinarof) cream, a once-daily, non-steroidal topical treatment for immune-mediated skin conditions.

Major companies operating in the atopic dermatitis market are Sanofi SA, Regeneron Pharmaceuticals Inc., Novartis International AG, Pfizer Inc., AbbVie Inc., Astellas Pharma Inc., Arcutis Biotherapeutics Inc., Asana Biosciences LLC, Dermavant Sciences Inc., Eli Lilly and Company, Galderma SA, Incyte Corporation, Bayer AG, Bausch Health Companies Inc., GlaxoSmithKline PLC, LEO Pharma A/S, Teva Pharmaceutical Industries Ltd., Allergan PLC, Menlo Therapeutics Inc., Johnson & Johnson, Merck & Co Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals Limited.

North America was the largest region in the atopic dermatitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atopic dermatitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the atopic dermatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the atopic dermatitis market by increasing costs of imported biologic drugs, active pharmaceutical ingredients, advanced formulation excipients, and manufacturing equipment. Pharmaceutical companies and healthcare providers in North America and Europe are most affected due to dependence on imported biologics, while Asia-Pacific faces pricing pressure on drug exports. These tariffs are raising treatment costs and affecting reimbursement dynamics. However, they are also encouraging local biologics manufacturing, regional formulation development, and increased investment in domestic dermatology drug production.

The atopic dermatitis market research report is one of a series of new reports that provides atopic dermatitis market statistics, including atopic dermatitis industry global market size, regional shares, competitors with a atopic dermatitis market share, detailed atopic dermatitis market segments, market trends and opportunities, and any further data you may need to thrive in the atopic dermatitis industry. This atopic dermatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Atopic dermatitis is a skin disorder that leads to dryness and itching. It is a long-lasting condition that develops over time and is not contagious.

The primary drug classes used to manage atopic dermatitis include corticosteroids, emollients/moisturizers, IL-4 and PDE4 inhibitors, calcineurin inhibitors, antibiotics, and others. Corticosteroids are anti-inflammatory medications that mimic cortisol and are employed to treat a range of conditions such as rheumatological disorders, rheumatoid arthritis, lupus, and atopic dermatitis. They can be administered via multiple routes, including topical, injectable, and oral, and are available through various distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The atopic dermatitis market consists of sales of biologics, CNI immunosuppressant drugs, and skin barrier emollients. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.